Life Sciences Today

Building Companies at the Edge of Science and Market - Life Sciences Today Podcast Episode 61

Danny Lieberman and John Lynn — Fri, 15 May 2026 11:00:54 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Jennifer Ernst, Co-Founder and CEO at Valion Bio (formerly Tivic Health). Ernst has built companies at the intersection of breakthrough science and market opportunity — from Xerox PARC’s open innovation lab to printed electronics to bioelectronic medicine.

As Co-Founder of Valion Bio, she took a handheld neuromodulation device from idea to FDA clearance in three years for under $3M, took the company public on Nasdaq, and executed a bold pivot into biopharmaceuticals.

In this episode, we dig into the hardest question in neuromodulation today: getting FDA approval is like base camp at Everest, and getting paid is reaching the summit — how do you get from base camp to the summit? And Ernst shares her remarkable journey from Xerox PARC to pioneering bioelectronic medicine — and what it really takes to build a business in neuromodulation.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

I think you’re the only person I know in the Life Sciences industry who has done devices and technology, and then pivoted from devices to biologics. Tell us about your journey. How did you make those transitions?
Is Valion Bio in good hands now that you’ve transferred over?
How many products does the company have in the portfolio right now?
For neuromodulation, getting FDA approval or doing a pivotal trial is like base camp at Everest — to get to market, you need to get all the way to the summit. How do you go from the base camp to the top of Everest?
The discourse in the public, on social media, and in the industry is that recruiting is a big problem. This seems to be true for certain areas of oncology, but not true for anything related to what you have done and chronic conditions. What do you think of that?
I saw an article out of the Weizmann Institute that claimed that they didn’t like Chinese Medicine, but Traditional Chinese Medicine has its own take on the body’s electrical signals. What do you think?
What do you think is the biggest anti-pattern in the neuromodulation/neuroscience space today?
What is next for you?

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube. Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn.

If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes.

Thanks so much for listening!

How AI is Replacing the Microsoft Word Protocol - Life Sciences Today Podcast Episode 60

Danny Lieberman and John Lynn — Fri, 08 May 2026 11:00:22 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Scott Chetham, Co-Founder and CEO at Faro Health. In this episode, I sit down with Chetham to explore why the clinical trial industry is still designing $100M+ studies in Microsoft Word — and what’s finally being done about it. Chetham shares his journey from the Gold Coast of Australia to the heart of San Diego’s biotech scene, and how two decades of hands-on clinical development experience led him to build an AI platform that can do in 60 minutes what previously took five experts three weeks.

From a published Merck study showing $130M in cost avoidance to becoming the first company to automate study builds directly into Veeva, Faro Health is quietly becoming the backbone of protocol design for 6 of the top 10 pharma companies. We also dig into the future of vertical integration in drug development — from molecule discovery all the way through automated clinical monitoring.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

What is an Australian doing in the US, working in clinical development? How did that happen?
Tell us what you’re doing at Faro Health.
Who are your sponsors, and how do you create value for them?
How do you capture value? What is your business model?
What’s your superpower?
What are three things you want to do for your sponsors in 2026?
I’ve been thinking about vertical integration, on and off, for the past ten years. How great would that be?
What is the biggest anti-pattern in the industry?

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

Israeli Medtech: Innovation Without an Ecosystem? - Life Sciences Today Podcast Episode 59

Danny Lieberman and John Lynn — Fri, 01 May 2026 11:00:43 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Shai Policker, Co-Founder and Managing Partner at Edge Medical Ventures! I sit down with Policker to challenge a provocative thesis: that Israeli medtech is trapped in a cycle of underfunding, walking-dead companies, and missed commercialization opportunities. I bring the data — $5.6B raised by 41 US medtech companies in 15 months, zero Israeli — and argue that the Israel Innovation Authority’s habit of writing small checks keeps entrepreneurs in perpetual poverty rather than building a self-sustaining ecosystem.

Policker pushes back with a counter-model: Edge VC’s venture studio approach, which starts from validated unmet needs sourced from large medical device corporations, builds companies from scratch, and bridges Israeli innovation to US commercial operations through a first-of-its-kind partnership with the state of New Jersey. The result: Israeli R&D capital efficiency meets American go-to-market expertise.

Our conversation covers the IAA’s evolving funding programs, why US investors still see Israel as a premier innovation hub, and what it actually takes to cross the ocean without crashing into the wall.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about your journey.
Break it down for our audience – when you say ‘a venture studio’, ‘we’re more of a VC’, and ‘we’re more hands on’, what does that mean?
Were you with the Israel Innovation Authority (IIA) for a while?
How much money are you managing right now?
My controversial opinion is that as a citizen of Israel, I would like my government investing more in the ecosystem and less in helping VC’s make more money. I know you don’t agree with this – so what is your view?
Would Israel as a country be better off if the government was creating commercialization infrastructure?
What is, in your opinion, the biggest anti-pattern in the Israeli medtech industry?

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

Revolutionizing Clinical Trial Protocols - Life Sciences Today Podcast Episode 58

Danny Lieberman and John Lynn — Fri, 24 Apr 2026 11:00:36 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Pedro Coelho, Founder and CEO at Biorce! In this episode, I sit down with Coelho to explore how his team went from flagging protocol mistakes to building AI that fixes them — and in doing so, became the first company to submit an AI-generated protocol to the FDA. Coehlo breaks down how Biorce can generate a best-in-class clinical trial protocol in under 5 minutes, why risk-based remote monitoring is the industry’s biggest anti-pattern, and what a “one-click clinical trial” could look like by the end of 2026.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about your journey – how does a European Founder like you, and a team like yours, get into a space that traditionally has been filled with American companies?
What is your value creation?
What is your business model? How do you make money from getting it right faster?
What are three things you want to do for your customers in 2026?
What is the biggest anti-pattern in clin-ops today?

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

NeuraLight is Reinventing Neurology's Gold Standard - Life Sciences Today Podcast Episode 57

Danny Lieberman and John Lynn — Fri, 17 Apr 2026 11:00:02 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Eddy Ben-Ami, Founder and CEO at NeuraLight! NeuraLight is tackling one of neurology’s biggest problems: how crudely we measure disease progression in conditions like Parkinson’s, MS, ALS, and Huntington’s. Despite MRI and gene sequencing, the current “gold standard” is pushing patients to test balance, or asking caregivers how hard it is to adjust clothes in bed.

Ben-Ami explains how NeuraLight replaces this with a 10‑minute, tablet-based eye-movement test using a standard camera. By leveraging decades of visual-system research (largely from primate studies), they extract functional biomarkers tied to specific neural pathways and brain regions. The result: objective, quantitative measures of brain function that are highly sensitive to change over time.

Over the past four years, NeuraLight has run large longitudinal studies on thousands of patients across multiple neurodegenerative diseases. In Parkinson’s, they’ve shown their metrics are 10x more sensitive to change than the existing clinical gold standard, with results being presented at ADPD in Copenhagen alongside the inventors of that standard.

Commercially, NeuraLight is already being paid as a per-test diagnostic in five pharma drug trials (Phase 1 and 2), where their measures serve as secondary/exploratory endpoints. Their moat is a growing, hard-to-replicate dataset linking eye movements to rich clinical data.

Looking ahead to 2026, they’re focused on successful readouts from ongoing trials, expanding into psychiatry, and bringing their technology into preventative-care platforms so even healthy people can track brain function—before catastrophe strikes.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about your journey.
What does NeuraLight do?
You do a lot of work with neurodegenerative diseases – Parkinson’s, MS, ALS, and Huntington’s, specifically – where are you holding right now in terms of product development?
What is your value creation?
In these drug trials, are you the primary endpoint or a secondary endpoint where they’re collecting an additional CRF together with their primary endpoint?
The primary endpoint is the gold standard, and no one will talk to you until you can show that you’re at least as good as the gold standard. So, at the end of the trial, have you thought about taking the data and doing a retrospective analysis to see how well your exploratory endpoint correlates with the primary endpoint? Can you piggyback on these trials to use the data to validate your measures?
What is your business model? How do you capture value from this?
What’s your moat? What prevents someone from doing the same thing you’re doing?
What are three things you want to do for your customers in 2026?
Do you need a 510(k) from the FDA to clear these diagnostics?
What is the biggest anti-pattern in your industry?

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

AI Agents Won't Replace CROs — They'll Save Them - Life Sciences Today Podcast Episode 56

Danny Lieberman and John Lynn — Fri, 10 Apr 2026 11:00:36 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Alison Holland, Chief Customer Officer at Medable! In this episode, I talk with Holland about how her journey from London nurse to Covance veteran to digital trial leader shapes Medable’s strategy.

Holland started at the bedside and then spent nearly 20 years at a major CRO – Covance. She learned where trials really break: overloaded sites, fragmented systems, and patients battling logistics instead of disease. Medable’s answer is a reusable SaaS platform plus tightly scoped AI agents—first for CRAs, then for TMF, and next for sites—that automate the manual, low‑value work while keeping humans firmly in the loop.

She walks through concrete wins: PRO compliance jumping from ~75% to 95%, 20% more primary endpoint data, and up to 100 hours saved in study startup by configuring from therapeutic‑area libraries instead of rebuilding from scratch.

Holland’s chosen industry anti‑pattern is “change fatigue”: an exhausted ecosystem that no longer believes transformation will stick. Her counter is precision use cases that deliver undeniable value, build momentum, and make it possible to say, credibly, “Yes, we can” this time.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about your journey.
Who are your customers and how do you create value for them?
What’s Medable’s sweet spot for the size of the customer, the kind of customer, or the phase of the study?
We saw this recurring pattern where the decisions would be taken in the last month before the trial, and a subpattern where, in the first two weeks, there would very often be a protocol revision. Is that your experience as well?
Do you have to do a custom build for every customer and every trial?
How do you capture the value?
Are we going to see AI Agents replacing CROs in our lifetime?
What are three things you want to do for your customers in 2026?
What is the biggest anti-pattern in the clinical R&D industry today?

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

Leadership, Moats, and the Next Phase of Clinical Research - Life Sciences Today Podcast Episode 55

Danny Lieberman and John Lynn — Fri, 03 Apr 2026 11:00:22 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Kim Boericke, the new CEO at Veristat! In this episode, I sit down with Kim to explore what it really takes to build and lead a durable CRO in a rapidly shifting life sciences landscape. We discuss Kim’s leadership journey, how value is created and captured in services-heavy businesses, and what Veristat is prioritizing for customers over the next 12 months. The conversation then goes deeper into the idea of moats—what makes a CRO genuinely hard to copy, what compounds over time, and how strategic decisions today shape defensibility five years out.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about your journey.
How do you create value for your customers?
How do you capture the value?
What are three things you’d like to achieve in the next 12-18 months?
What makes a CRO genuinely hard to copy?
What compounds over time? How do the strategic decisions you make today shape out defensibility five years from now?

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

Virtual Labs with Josh Haimson - Life Sciences Today Podcast Episode 54

Danny Lieberman and John Lynn — Fri, 27 Mar 2026 11:00:56 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Josh Haimson, Co-Founder and CEO at Inductive Bio! Josh Haimson joins me to talk about how their virtual lab can run millions of in silico experiments to predict how molecules will behave in the body and surface the strongest hypotheses to test in the wet lab.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about your journey.
How do you create value for your customers?
How do you measure the value?
What are three things you’d like to achieve in the next 12-18 months?

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

Beyond the EMR: Simon Arkell Rewires Clinical Trials - Life Sciences Today Podcast Episode 53

Danny Lieberman and John Lynn — Fri, 20 Mar 2026 11:00:04 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Olympian-turned-founder Simon Arkell joins Life Sciences Today to explain how Ryght.ai is reinventing clinical trial site selection. He unpacks digital twins for 100,000+ sites, AI agents, and why EMR-centric models are an anti-pattern—showing how sponsors can slash enrollment risk, save hundreds of millions, and scale globally.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about your journey.
How do you create value for your customers?
How do you measure the value?
What are three things you’d like to achieve in the next 12-18 months?

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

Global Medical Data Infrastructure for AI Systems with MedSyntra - Life Sciences Today Podcast Episode 52

Danny Lieberman and John Lynn — Fri, 13 Mar 2026 11:00:00 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Asta Ratkeviciene, Co‑Founder and CEO at MedSyntra. In this episode of Life Sciences Today, I talk with Ratkeviciene about building a global, ethically sourced medical imaging data infrastructure across radiology, pathology, oncology, and women’s healthcare. Ratkeviciene explains how MedSyntra aggregates and de-identifies millions of imaging studies, provides a highly curated data marketplace and platform for institutions that require data sovereignty, and partners with clinical experts for annotation and external teams for model development. They discuss why imaging is the core focus, how population differences can degrade AI performance across geographies, MedSyntra’s evolving business model, and the biggest anti‑patterns Ratkeviciene sees in the medical AI ecosystem today.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

What’s the most important thing people misunderstand about medical imaging data?
Who must have this infrastructure before they can deploy serious AI?
When did you realize you weren’t building a dataset—but infrastructure?
What early decision optimized for long-term trust rather than speed?
Where does ethical data sourcing actually slow you down commercially?
Have you walked away from data that would have helped the business—but violated your principles?
Do you think ethical language is sometimes used to hide poor data practices?
Why do imaging AI models quietly fail when they cross borders?
When does population bias show up—training or deployment?
Why can’t this be solved with more data alone?
How do you reconcile local data control with global AI learning?
Do we end up with federated intelligence—or fragmented ecosystems?
What’s harder: collecting imaging data or producing clinically meaningful labels?
If annotation quality doubled, what would that unlock that most people aren’t expecting?
What’s the biggest anti-pattern you see in medical AI today?
Ten years from now, what will seem obvious about medical imaging AI that people are still ignoring today?

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

How PathKeeper Surgical is Changing Spine Surgery - Life Sciences Today Podcast Episode 51

Danny Lieberman and John Lynn — Fri, 06 Mar 2026 11:00:03 -0500

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Erez Lampert, Founder and CEO at PathKeeper Surgical! I talk with Lampert about his journey from Israel’s aerospace industry and Invisalign’s Itero scanner to founding PathKeeper in 2018–2019. We dig into the core problem in spine surgery—surgeons “flying blind” between low‑cost, high‑radiation fluoroscopy and ultra‑expensive robotics—and how PathKeeper offers a third way using optical 3D imaging and AI. Erez explains their dual business model (capital + disposables, plus a “razor blade” model via implant partners in a $10B US spine market), and how strategic deals with High Ridge Medical (Zimmer Biomet spine) and Vizient unlock scalable US commercialization without a 50‑person direct sales team. The conversation challenges the myth that Israelis don’t know how to sell in the US, reframing success as understanding gatekeepers, GPOs, and distribution science rather than just raising $50M and hiring a big sales force.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

What problem are spine surgeons facing today, and why is “flying blind” so dangerous?
How does PathKeeper’s 3D imaging + AI platform actually work in the OR, and how is it different from fluoroscopy and million‑dollar robots?
What is PathKeeper’s business model, and how does the implant “razor blade” model create leverage in a $10B US spine market?
How did the High Ridge Medical and Vizient deals come together, and what do they change for commercialization?
Why is the common investor advice, “raise $50M and build a huge US sales team’ the wrong playbook here?
What are the biggest anti‑patterns in the spine/med‑device industry today?

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

AI Insights in Pharma with Protai - Life Sciences Today Podcast Episode 50

Danny Lieberman and John Lynn — Fri, 27 Feb 2026 11:00:55 -0500

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Kiril Pevsner, Co-Founder and CTO at Protai. We kick this episode off by discussing how Pevsner creates and captures value with pharma. Then we talk about where AI meaningfully shapes decisions in the early discovery and preclinical work. Next, we take a look at where pharma teams hesitate to act on AI-driven insights, even when the science looks strong. We conclude this episode with Pevsner sharing where he doesn’t think AI should be used in drug discovery or development, at least with today’s tools and incentives.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

How do you create and capture value with pharma?
From what you see building Protai, where does AI meaningfully shape decisions in early discovery or preclinical work — especially decisions that partners or pharma teams later have to trust?
Where do pharma teams hesitate to act on AI-driven insight, even when the science looks strong?
Where do you think AI should not be used yet in drug discovery or development, at least with today’s tools and incentives?

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

Building a Rare Disease Ecosystem with Rafa's Moonshot - Life Sciences Today Podcast Episode 49

Danny Lieberman and John Lynn — Fri, 20 Feb 2026 11:00:20 -0500

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Sagi Sigali, Father and Founder of Rafa’s Moonshot – a non-profit dedicated to Landing a Cure for STXBP1. Sagi and I discuss how Rafa’s Moonshot is turning a rare genetic disorder (STXBP1) into an investable, de‑risked therapeutic opportunity. Sagi explains how his tech/entrepreneur background shapes a for‑profit mindset around fundraising, biopharma partnerships, and making rare disease indications attractive to industry. They cover building a global network, leveraging grants and consortia, working with academia/CROs, and planning the flip from nonprofit to for‑profit. They also dig into industry “anti‑patterns,” including copy‑paste development strategies, and explore a strategy to start from the drug label and work backwards. Sagi closes with his vision for a complete STXBP1 solution, a new CNS neurogenetic research center in Israel, and a stronger Israeli life sciences ecosystem.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

How does Rafa’s Moonshot actually create value for drug and biotech companies working on STXBP1?
What does the market and patient landscape look like for STXBP1 as a rare disease?
How has your background as a serial tech entrepreneur influenced your strategy in rare disease therapeutics?
What are you doing to make STXBP1 attractive enough to enter big‑pharma pipelines?
How do conversations with academics, clinicians, CROs, and biopharmas translate into real progress?
What is your consortium model, and how do grants and non‑dilutive funding fit into it?
How are you using CROs in preclinical work and thinking about IP and cell line development?
What do you see as the biggest anti‑pattern in rare disease/drug development today?
What are the top three things you want to achieve for STXBP1 patients in the next year?
What is your five‑year vision for STXBP1, for Rafa’s Moonshot, and for the Israeli life sciences ecosystem?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

Increasing Productivity in Clinical Research - Life Sciences Today Podcast Episode 48

Danny Lieberman and John Lynn — Fri, 13 Feb 2026 11:00:13 -0500

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Zina Sarif, Founder and CEO at Yendou.

Zina Sarif is one of the most dynamic and inspirational founders I’ve met. She grew up in Morocco until age 20 and, after her PhD in biology, spent a decade in cancer drug discovery before leading clinical research at Parexel and PhIII oncology trials at AstraZeneca. Driven by the vision of a cancer-free world, she built Yendou to accelerate research, streamline site operations, and deliver life-saving treatments faster.

Yendou streamlines the site selection process and the interaction between CROs, sponsors, and sites, producing 2X improvements in productivity. One of my other guests from Lindus Health said it best, “Everyone is more productive with Yendou. We accelerated feasibility timelines by 50% while reducing manual follow-ups by 70%.”

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell us about your personal journey—how did you get from consulting and Viva to leading Ledger Run?
Who are your customers, and what specific problems are you solving for them?
How do you create value for sponsors and CROs in clinical trial site selection and relationship management?
How do you capture that value—what does your business/revenue model look like?
What is the biggest anti–design pattern you see in the industry right now?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

Payments, Pain, and Pragmatic AI in Clinical Trials - Life Sciences Today Podcast Episode 47

Danny Lieberman and John Lynn — Fri, 06 Feb 2026 11:00:28 -0500

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is John Chinnici, CEO at Ledger Run. I talk with Chinnici about his journey from consulting (Andersen, IBM) to Viva, where he helped launch and grow Vault, and eventually to leading Ledger Run. Ledger Run focuses on the “unsexy but critical” operational layer of clinical trials: contracting and paying investigative sites. Chinnici explains how delayed, incorrect, and bureaucratic payments have become an accepted but damaging status quo in clinical research, despite sites running on razor-thin margins.

Ledger Run’s SaaS platform and services aim to ensure strict contract compliance, dramatically improve operational efficiency, and turn reliable payments into a competitive advantage for sponsors in site recruitment. Chinnici also argues that a major industry anti-pattern is pouring AI investment into volatile early research use cases while underinvesting in high-ROI operational applications such as automating invoice processing and other repetitive payment workflows.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell us about your personal journey—how did you get from consulting and Viva to leading Ledger Run?
Who are your customers, and what specific problems are you solving for them?
How do you create value for sponsors and CROs in clinical trial payments and contracts?
How do you capture that value—what does your business/revenue model look like?
What are three things you want to do for your customers in the next 12–18 months to make them insanely happy?
What is your competitive moat—what makes Ledger Run hard to copy compared with large CROs and other players?
What is the biggest anti–design pattern you see in the industry right now?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

Beyond the Science by Gary Zammit - Life Sciences Today Podcast Episode 46

Danny Lieberman and John Lynn — Fri, 30 Jan 2026 11:00:50 -0500

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Gary Zammit, PhD, President and Chief Executive Officer at Clinilabs. We often imagine medical breakthroughs as the result of data, protocols, and lab science alone. But Gary Zammit has seen firsthand that bringing therapies to patients requires far more: resilient teams, disciplined processes, and cultures that can weather setbacks.

In his new book, Beyond the Science: How People, Process, and Systems Transform the Business of Life Sciences, Zammit offers readers an inside look at the real drivers of innovation. From navigating near-bankruptcy at Clinilabs to helping advance more than twenty therapies across thirteen CNS indications, his stories highlight the human and organizational forces that shape the future of medicine.

Whether you are in healthcare, business leadership, or organizational strategy, Beyond the Science is both a practical guide and an urgent call to action: to build organizations as resilient and innovative as the science they support because patients are waiting.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about your journey. How did that shape you as a leader, and how did those experiences lead you to write Beyond the Science?
From your vantage point at Clinilabs, what’s the most misunderstood people-or-process failure in drug development — and how does Clinilabs create value by solving it? How do you prove to sponsors that you’ve actually solved it?
CROs often look interchangeable from the outside, yet Clinilabs has built a reputation in one of the most challenging therapeutic areas. Where does your defensibility — your ‘moat’ — really come from? What does Clinilabs do that sponsors or big site networks like Velocity Clinical can’t easily copy?
In the closing of the book, you emphasize pushing beyond ‘good enough’ and building teams, systems, and processes that strive for greatness. Looking ahead 12–18 months, what are the three things you want to do for your customers that will raise the bar — things that will materially improve the way CNS trials get run?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

Almased - Natural Health Superfood Protein - Life Sciences Today Podcast Episode 45

Danny Lieberman and John Lynn — Fri, 23 Jan 2026 11:00:36 -0500

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guests today are Jamie Luu, RDN, LDN, Strategy and Nutrition Manager, and Ronja Kröger, Nutrition & Product Expert, M. Sc. Nutritional and Food Sciences at Almased. The Almased-type diet can boost natural satiety signals via GLP-1 and PYY — that is real and meaningful. But the new GLP-1-RA drugs go much further: they hijack those same signals, ramp them much higher, and translate into large weight losses in patients with obesity. So the diet is a “natural nudging” of the system; the drugs are a strong “override” of the system.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

You’re showing that the Almased high-protein diet raised GLP-1 and PYY levels — how would you compare that to what we know about the injectable GLP-1 drugs (like Ozempic)? Is the mechanism the same, just a different scale, or is there something qualitatively different going on?
I read the IIS paper from 2021 and the results are impressive. Given that the diet intervention was isocaloric (same calories) and short-term, yet still changed appetite-hormone profiles — is Almased complementary to GLP-1 drugs like Ozempics or a preventive/maintenance tool for people who aren’t yet eligible for—or don’t want—drugs?
For someone who isn’t on GLP-1 medication, what are realistic expectations of using a high-protein total diet replacement in terms of appetite regulation, hormone effects, and perhaps weight maintenance? And how should they view that in the context of the new drug therapies that dominate headlines?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

Clinical Trials with Denali Rose - Life Sciences Today Podcast Episode 44

Danny Lieberman and John Lynn — Fri, 16 Jan 2026 11:00:42 -0500

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Denali Rose, VP at Veeva, and Co-Host of Note to File. Rose’s parents are outdoors people and named her after the national park in Alaska. Personally, this is one of the most fun shows we’ve ever done. ‘Nuff said – get in and listen! She is Vice President Sales & Strategy, Site Solutions at Veeva. That’s her day job – she’s also the Co-Host and Producer of the Note To File podcast. She’s focused on delivering solutions for clinical research sites, guiding the sales cycle, and aligning strategy to drive impact and growth. She’s super smart and extremely experienced in the patterns and anti-patterns in the clinical trial industry.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about your journey.
How did you get into podcasting, and why do you think it’s important?
CROs are part of the problem, and therefore, they cannot be a part of the solution; sites will inherit the Earth – what is your take on this? Do you think CROs are part of the problem and therefore can’t be part of the solution? Do you think sites will actually inherit the Earth?
What other hats do you wear besides ClinOps?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

Data Integrity, Synthetic Data, and Strategic Moats in Healthcare Analytics - Life Sciences Today Podcast Episode 43

Danny Lieberman and John Lynn — Fri, 09 Jan 2026 11:00:15 -0500

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Daniel Blumenthal, VP of Strategy at MDClone. I talk with MDClone’s VP Strategy about how the company evolved from an early synthetic data pioneer (2016) into a broader data-access and data-extraction platform in a now-crowded market (Snowflake, Oracle, Epic, many synthetic data vendors). Our discussion explores MDClone’s core “nexus” capability of extracting privacy-protected, row-level longitudinal patient data from heterogeneous healthcare systems and producing different types of synthetic data for distinct use cases (research, cross-site collaboration, model development/validation).

A major theme is the industry shift from focusing mainly on data access/privacy to treating data integrity and trust as the new frontier and core IP for health systems, pharma, and AI. We debate strategic moats (product vs. project, partnerships vs. competition, where MDClone controls the data supply chain) and how MDClone can remain indispensable as AI and analytics mature. The episode closes with how all this ultimately must translate into better patient outcomes and trustworthy next-generation AI models.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

How has MDClone evolved over the nine years since you became the first employee outside Israel?
Synthetic data is now crowded and partially commoditized; what still differentiates MDClone in 2025?
In the CIA triad (confidentiality, integrity, availability), is the real new frontier now data integrity rather than access/privacy?
What specific part of the healthcare data supply chain does MDClone control that large partners like Snowflake, Epic, or Palantir cannot easily replace?
Is MDClone ultimately a product company or a series of bespoke projects, given all the customization and services required?
How do you use synthetic data differently for distinct utilities (knowledge gain, cross-site collaboration, model development/validation)?
What do you think about trust, privacy, and the patient’s role when patient data is treated as core IP for organizations?
How can MDClone help ensure that AI models (including LLMs) are trained and validated on high-integrity, trustworthy data rather than “shitty data”?
In a world where every major player can analyze clinical data, what will make MDClone indispensable?
How do you see MDClone’s role in directly improving patient outcomes through better data and analytics?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

Brain Health, Behavior, and the Future of Dementia Prevention - Life Sciences Today Podcast Episode 42

Danny Lieberman and John Lynn — Fri, 02 Jan 2026 11:00:09 -0500

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is David Bates, Founder and CEO at Linus Health. I talk with David Bates about Linus Health’s mission to transform brain health from late-stage “sick care” to proactive, preventive care. David explains his journey from signal detection research and investing in built-environment technologies to founding Linus Health around the insight that behavior is the primary observable output of the brain. We discuss Linus’s 3-minute digital cognitive assessments that turn rich behavioral signals into thousands of digital biomarkers, enabling highly sensitive, objective measurement of cognition and early detection of impairment years before symptoms. Our conversation covers the company’s focus on primary care and health systems as core customers, revenue and ROI in fee-for-service and value-based care, and Linus’s data moat of large, diverse, longitudinal datasets. We explore how clinically integrated, consumer-accessible tools could make brain health monitoring continuous—like a “blood pressure cuff for the brain”—and why this paradigm shift is critical for both healthcare delivery and drug development.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

How did your background in signal detection, multimodal sensing, and investing lead you to found Linus Health?
What does Linus Health’s platform actually do, and how are your digital assessments different from traditional paper-based cognitive tests?
Who are your main customers today (primary care, health systems, pharma, payers), and how do you create and capture value across these different buyer types?
How do you translate thousands of digital biomarkers and AI/ML models into clinically meaningful insights, and how often are your models updated?
What is your long-term vision? Is the biggest opportunity in supporting drug development, or in becoming a clinically integrated, mass-market “Internet of bodies” brain health platform for consumers?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

Real-Time Pharma Insights: Philip Poulidis on Scaling ODAIA AI

Danny Lieberman and John Lynn — Fri, 26 Dec 2025 11:00:45 -0500

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Philip Poulidis, CEO at Toronto-based ODAIA. Poulidis is tackling one of pharma’s biggest bottlenecks: slow, siloed commercial analytics. Spun out of academic research, ODAIA’s real-time AI platform unifies patient and HCP journey data, replacing months-old reports with dynamic insights that help reps, liaisons, and marketers target the right physicians at the right time — improving prescriptions, outcomes, and patient access. regulated by the USDA/FDA.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about your journey.
Tell me about ODAIA AI.
Who are your customers?
How do you create value?
How do you capture value from customers?
What are three things you want to do for your customers in the next 12-18 months?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

Freeze-Drying the Future: 43 Years of Innovation at OFD - Life Sciences Today Podcast Episode 40

Danny Lieberman and John Lynn — Fri, 19 Dec 2025 11:00:39 -0500

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Walt Pebley, Chief Scientific Officer at OFD Life Sciences. With over four decades in lyophilization, Walt Pebley has helped OFD become the gold standard in stabilizing probiotics, biologics, and therapeutics. His journey — from personal tragedy to pioneering new delivery platforms — highlights how freeze drying shapes the future of medicine, from shelf-stable powders to novel formats for pain, diabetes, and neurology drugs, food, and dietary supplements regulated by USDA/FDA.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about your journey.
Tell me about OFD Life Sciences.
Who are your customers?
How do you create value?
How do you capture value from customers?
What are three things you want to do for your customers in the next 12-18 months?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

Large Quantitative Models with SandboxAQ - Life Sciences Today Podcast Episode 39

Danny Lieberman and John Lynn — Fri, 12 Dec 2025 11:00:33 -0500

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Tiffany Callahan, Lead Architect of Agentic AI Systems at SandboxAQ. As a physicist, I love her approach to Large Quantitative Models trained on physics, chemistry, biology, and math to model the real world.

Most of the companies in this space are building statistical models by:

integrating large datasets for target identification by analyzing genomic and multi-omic data
virtual screening to identify promising drug candidates
novel molecule design and property prediction (toxicity, efficacy, pharmacokinetics)
clinical trial optimization through patient selection and outcome prediction
drug repurposing by finding new uses for existing drugs

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about your journey.
Tell me about SAIR.
Who are your customers?
How do you create value?
How do you capture value from customers?
What are three things you want to do for your customers in the next 12-18 months?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

Evidexa - Validating Healthtech with Evidence - Life Sciences Today Podcast Episode 38

Danny Lieberman and John Lynn — Fri, 05 Dec 2025 11:00:58 -0500

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Jeff Gombala, Founder and CEO at Evidexa. Jeff Gombala started Helios Innovation with an idea that seems obvious – use expert knowledge and AI models to validate healthtech and medtech products.

We’re going to talk about Jeff’s journey, the value they are creating, how they’re turning that into a business, and where they want to take customers by 2026.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about your journey.
How do you create value for your customers?
How do you capture value?
What are three things you’d like to achieve for your customers in the next 12 months?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

Redefining Healthcare Research with Briya AIRE - Life Sciences Today Podcast Episode 37

Danny Lieberman and John Lynn — Fri, 28 Nov 2025 11:00:29 -0500

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is David Lazerson, Co-Founder and CEO at Briya.

Briya started in 2020 with a bold idea — using cryptography and zero-knowledge proofs to make healthcare data shareable, secure, and compliant. Fast forward to today, they’ve just launched Briya AIRE, a clinical-grade AI research platform that promises to let researchers ask questions in plain English and get scientifically robust answers back — without writing code.

We’re going to talk about David’s journey, the value Briya is creating, how they’re turning that into a business, and where they want to take customers by 2026.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

What made you start with something as gnarly as zero-knowledge proofs for healthcare data?
At what point did you realize infrastructure wasn’t enough, that people wanted insights, not just secure pipes?
What customer conversations tipped you off that AI was the next layer?
For a researcher using AIRE, what’s the moment when the lightbulb goes on?
Which use case best shows the value — the one where you thought, ‘okay, this is working’?
How quickly can a researcher go from a question in plain English to a publishable-level output?
Validation is one thing — but startups live or die on turning that into repeatable business. What did you have to prove to your Series A investors to show Briya could cross that chasm?
I know you probably can’t share exact revenue, but when investors leaned in, what was the strongest signal they saw that Briya wasn’t just another pilot project? Contracts signed, pipeline size, or something else?
If we sit down again in 18 months, what would you want to point to as real traction?
What’s the one thing you think customers will be most surprised that Briya can do for them by 2026?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

Bioconvergence at The Israel Innovation Authority - Life Sciences Today Podcast Episode 36

Danny Lieberman and John Lynn — Fri, 21 Nov 2025 11:00:07 -0500

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Shai Melcer, Head of the National Program for Bioconvergence at The Israel Innovation Authority. We kick this episode off by first learning what bioconvergence is. Then we talk about who The Israel Innovation Authority’s customers are. Next, we examine why this is such a unique opportunity for Israel. But no opportunity is without its competition, so we talk about how Melcer is competing with cyber and defense — which are huge sectors here. Melcer then also shares how he is competing against big companies like Sandbox AQ. Next, we discuss how The Israel Innovation Authority creates and captures value. Lastly, we conclude this episode with Melcer sharing three things he wants to do for his customers.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

What is bioconvergence?
Who are your customers?
Why is this a unique opportunity for Israel?
How do you compete with cyber and defense, which are huge sectors here?
How do you compete with companies like Sandbox AQ, which spun off from Google quantum computing, raised $950M, and just released the largest publicly available binding affinity dataset with co-folded 3d structures on Hugging Face?
How do you create value?
How do you capture value from your customers?
What are 3 things you want to do for your customers?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

From Math to Medicine: Yann Gaston-Mathé's Mission to Transform Drug Discovery with AI and Robotics - Life Sciences Today Podcast Episode 35

Danny Lieberman and John Lynn — Fri, 14 Nov 2025 11:00:10 -0500

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Yann Gaston-Mathé, Co-Founder and CEO at Iktos.

Iktos combines AI drug discovery with a robot chemist – AI designs novel compounds considering synthesis constraints, and robots automatically synthesize compounds (100 reactions in parallel vs 2 manual).

Trained as a mathematical engineer, Yann Gaston-Mathé crossed from numbers into biology, carrying a belief that drug discovery could be faster, smarter, and more humane. With Iktos, he’s bringing that vision to life — combining generative AI and robotics to redesign how medicines are designed, made, and tested, with the goal of delivering better therapies in less time.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about your journey.
Tell me about Iktos.
Who are your customers?
How do you create value?
How do you capture value from customers?
What are 3 things you want to do for your customers in the next 12-18 months?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

Precision Oncology Alliance with Caris Life Sciences - Life Sciences Today Podcast Episode 34

Danny Lieberman and John Lynn — Fri, 07 Nov 2025 11:00:46 -0500

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is James Hamrick, MD, MPH, Chairman of the Caris Precision Oncology Alliance at Caris Life Sciences. By combining massive amounts of genomic, transcriptomic, and proteomic data with clinical outcomes, Caris has created one of the largest and most comprehensive multimodal databases of combined molecular and clinical outcomes data in the world – more than 600,000 matched patient records and growing.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about your journey.
How do you create value for your oncology treatment center partners in the POA?
How do you capture the value?
What are 3 things you’d like to achieve for your customers in the next 12 months?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

Hybrid Intelligence with Carta Healthcare - Life Sciences Today Podcast Episode 33

Danny Lieberman and John Lynn — Fri, 31 Oct 2025 11:00:01 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Aaron Brauser, General Manager Life Sciences at Carta Healthcare.

AI should work in synergy with clinical expertise. This “Hybrid Intelligence” approach propelled Carta Healthcare to become a leader in clinical data abstraction, serving health systems and pharma companies. Their platform leverages a combination of AI, LLMs, and clinically guided expert models to analyze EHR data in real time, instantly matching patients to clinical trials. Additionally, the solution captures and makes available all the key clinical data from the unstructured notes to allow it to be imported back into the EMR, improving research and other clinical uses.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about your journey.
How do you create value for your drug company customers?
How do you capture the value?
What are 3 things you’d like to achieve in the next 12 months?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

Clean and Structured Text with emtelligent - Life Sciences Today Podcast Episode 32

Danny Lieberman and John Lynn — Fri, 24 Oct 2025 11:00:39 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Tim O’Connell, Founder and CEO at emtelligent. Tim O’Connell and Anoop Sarkar started emtelligent in 2016 with a need that Tim had (and still has) as a practicing radiologist. How do you take the massive volume of unstructured text in healthcare and put it into a clean, structured format?

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about your journey.
How do you create value for your drug and device customers?
How do you measure the value?
What are 3 things you’d like to achieve in the next 12 months?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

From Personal Struggle to Global Solution: Wessam Sonbol’s Mission to Bring Trials Home - Life Sciences Today Podcast Episode 31

Danny Lieberman and John Lynn — Fri, 17 Oct 2025 11:00:33 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Wessam Sonbol, Founder and CEO at Delve Health. Sonbol founded Delve Health after watching his mother struggle to access a cancer trial, despite his 25 years in the industry. His company now brings trials into patients’ homes with wearables, AI agents, and multilingual support — aiming for 90%+ compliance, cutting rare-disease dropout rates, and automating many of the manual tasks that bog down site coordinators.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about your journey.
Tell me about Delve Health.
Who are your customers?
How do you create value?
How do you capture value from customers?
What are 3 things you want to do for your customers in the next 12-18 months?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

Drug Development with Certara - Life Sciences Today Podcast Episode 30

Danny Lieberman and John Lynn — Fri, 10 Oct 2025 11:00:03 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Rajesh Krishna, Senior Distinguished Scientist at Certara and a recognized leader in drug development. With 25+ years of experience, he’s shaped model-informed strategies for biologics, vaccines, and small molecules, and is consistently ranked among the top 2% of influential scientists.

Drug development is too slow and expensive. Certara helps companies design better trials, predict outcomes, and reduce risk using modeling, simulation, and AI. The goal is straightforward: make it faster and more efficient to bring safe and effective drugs to patients.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about your journey.
Tell me about Certara.
Who are your customers?
How do you create value?
How do you capture value from customers?
What are 3 things you want to do for your customers in the next 12-18 months?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

Business Development with BDaaS - Life Sciences Today Podcast Episode 29

Danny Lieberman and John Lynn — Fri, 03 Oct 2025 11:00:56 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Tigran Arzumanov, Founder and CEO at Basel-based BDaaS.

BDaaS helps US life science companies expand into Europe by solving one of their toughest problems: hiring business development talent. Instead of choosing between juniors without connections and seniors without the energy for outreach, BDaaS offers an experienced EU sales team, complete with infrastructure and tech stack, ready to start immediately in a flexible engagement model.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about your journey.
Tell me about BDaaS.
Who are your customers?
How do you create value?
How do you capture value from customers?
What are 3 things you want to do for your customers in the next 12-18 months?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

Long-Term Patient Follow-Up with Medable - Life Sciences Today Podcast Episode 28

Danny Lieberman and John Lynn — Fri, 26 Sep 2025 10:00:55 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Pamela Tenaerts, Chief Medical Officer at Medable. Tenaerts talks about how they improve accessibility for patients in the 15-year follow-up period mandated by the FDA for patients in gene therapy trials. Patients often travel from far (even internationally) for treatment, sponsors have to pay for infrastructure costs for maintaining multiple sites, and patients have to deal with parking and logistics issues at hospitals.

Medable’s eCOA software enables patients to use their phones to report on outcomes, stay close to home, and do blood work and imaging in local clinics. The benefits for drug company customers are reduced infrastructure costs, better patient retention, faster data collection, and improved regulatory compliance.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about your journey to Medable.
How do you create value for drug companies?
How do you measure the value?
What are 3 things you’d like to achieve in the next 12 months?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

Data Cleaning and Standardization with Cornerstone AI - Life Sciences Today Podcast Episode 27

Danny Lieberman and John Lynn — Fri, 19 Sep 2025 11:00:59 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Viraj Narayanan, CEO at Cornerstone AI. Cornerstone uses AI to clean and standardize healthcare data. Cleaning healthcare data is a non-sexy job that consumes staggering amounts of resources in the industry. When Narayanan was at McKesson, he had 25 PhD biostatisticians who spent 70% of their time on data cleaning.

Cornerstone AI reduces data cleaning time from 8-12 weeks to days. They maintain human oversight while accelerating processes, improve data quality while reducing processing time, and scale data volume without a linear time increase. Their primary long-term growth driver is biopharma companies. Data companies like Komodo Health embed Cornerstone technology in the data pipeline for laboratory data cleanup and LOINC code assignment. They improve LOINC assignment rates from 20-30% to 80-90%.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about your journey to Cornerstone AI.
How do you create value for your drug and data customers?
How do you measure the value?
What are 3 things you’d like to achieve in the next 12 months?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

Digital Twins with Unlearn - Life Sciences Today Podcast Episode 26

Danny Lieberman and John Lynn — Fri, 12 Sep 2025 11:00:07 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Aaron Smith, Co-Founder of Unlearn, to talk about how they use digital twins to save resources in clinical trials and fast-track the most promising therapies.

Unlearn increases the statistical power of clinical trials with fewer patients using disease-specific ML models. Leading biopharma companies are applying Unlearn’s technology in real-world clinical trials today. Abbvie is accelerating Clinical Development in Alzheimer’s Disease using Unlearn to reduce control arm size by 33% and reduce time to complete clinical trials by 4+ months.

Unlearn customers design and run smaller RCTs that maintain power or boost it without additional study participants. This approach is qualified by the EMA and aligns with current FDA guidance.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about your journey to Unlearn?
How do you create value for your drug and device customers?
How do you measure the value?
What are 3 things you’d like to achieve in the next 12 months?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Thanks so much for listening!

Precision Medicine for Autoimmune Diseases with Promise Bio - Life Sciences Today Podcast Episode 25

Danny Lieberman and John Lynn — Fri, 05 Sep 2025 11:00:04 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Ronen Veksler, Co-Founder and CEO at Promise Bio. Promise Bio is an early-stage tech-bio company coming out of AION Labs in Israel with strategic investors – AstraZeneca and Pfizer. They’ve built a cloud-based AI platform that uses advanced mass spectrometry-based proteomics and provides value for pharmaceutical companies in 4 ways: identifies new drug targets, predicts treatment response, analyzes the mechanism of action, and supports pathway engagement analysis.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about your journey to Promise Bio?
Who are your customers?
How do you create value for your customers?
How do you capture value from them?
What are 3 things you want to achieve for your customers in the next 12-18 months?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today on your favorite podcasting platform:

Thanks so much for listening!

Therapeutic Response with Genialis - Life Sciences Today Podcast Episode 24

Danny Lieberman and John Lynn — Fri, 29 Aug 2025 11:00:50 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Miha Štajdohar, Co-Founder and CTO at Genialis. Genialis develops and markets an AI supermodel that can predict Therapeutic Response for cancer patients.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about your journey to Genialis?
Who are your customers?
How do you create value for your customers?
How do you capture value from them?
What are 3 things you want to achieve for your customers in the next 12-18 months?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today on your favorite podcasting platform:

Thanks so much for listening!

Electronic Benefit Verification with Surescripts - Life Sciences Today Podcast Episode 23

Danny Lieberman and John Lynn — Fri, 22 Aug 2025 11:00:05 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. I am once again taking over for Danny to sit down with Andrea Douglas, Director Business Development Life Sciences at Surescripts, to talk about their electronic benefit verification! We kick this episode off by discussing some of the challenges behind benefit verification today. Then, we talk about what exactly electronic benefit verification is and how it works. Next, Douglas explains why life sciences companies should work with Surescripts for electronic benefit verification. We then take a look at other services out there to see how Surescripts’ electronic benefit verification differs from them. Lastly, we examine the impact electronic benefit verification has on patients of life sciences companies.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

What are some of the challenges with benefit verification today?
What is electronic benefit verification, and how does it work?
Why should a life sciences company work with Surescripts for electronic benefit verification?
How is Surescripts electronic benefit verification different than other services like it out there?
What’s the impact on patients of life sciences companies using electronic benefit verification?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Surescripts is a proud sponsor of Healthcare Scene

Be sure to subscribe to the Life Sciences Today on your favorite podcasting platform:

Thanks so much for listening!

Surescripts is a proud sponsor of Healthcare Scene.

AI Teammates with Tilda Research - Life Sciences Today Podcast Episode 22

Danny Lieberman and John Lynn — Fri, 15 Aug 2025 11:00:15 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Ram Yalamanchili, Founder and CEO at Tilda Research. Tilda Research develops and markets a system of AI teammates that work alongside sponsor, site, and CRO research teams. AI Teammates for Clinical Trials is a system of agents – with product flavors for sites, sponsors, and CROs.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Who are your customers?
How do you create value for your customers?
How do you capture value from them?
What are 3 things you want to achieve for your customers in the next 12-18 months?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today on your favorite podcasting platform:

Thanks so much for listening!

First-in-Human Trials with Bioaccess - Life Sciences Today Podcast Episode 21

Danny Lieberman and John Lynn — Fri, 08 Aug 2025 11:00:07 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Julio Martinez-Clark, CEO at Bioaccess, a CRO that specializes in executing first-in-human trials outside the US. Bioaccess empowers Medtech and Biopharma innovators to accelerate early feasibility studies and first-in-human trials via Latin America, Eastern Europe, and Australia’s 40% faster approvals, 50% quicker enrollment, and 30% lower costs.

For sponsors, Bioccess is selling time – faster to first-in-human medical device trials and faster to pivotal trials and FDA approval.

For countries like Colombia and El Salvador, Bioaccess creates jobs, promoting economic growth, improving healthcare, increasing research and development, and gaining international recognition.

And for patients in LATAM, Bioaccess is providing accessibility to innovative medical devices.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Who are your customers?
How do you create value for your customers?
How do you capture value from them?
What are 3 things you want to achieve for your customers in the next 12-18 months?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today on your favorite podcasting platform:

Thanks so much for listening!

Civica Rx with Carter Dredge - Life Sciences Today Podcast Episode 20

Danny Lieberman and John Lynn — Fri, 01 Aug 2025 11:00:41 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. I took over for Danny this episode to sit down with Carter Dredge, Executive Director of the Intermountain Health Institute, to talk about Civica Rx and some of the other unique models that Dredge and his team are working on at Intermountain Health Institute! We kick this episode off by discussing why Intermountain decided to get into the pharma and life sciences business. Then we talk about what makes Civica Rx different from the traditional life sciences companies. Next, we take a look at finances to see what some of the economic dynamics are at play with Civica Rx. Dredge then shares with us some examples of the impact of this work. Then Dredge walks us through what life sciences should understand about Civica’s efforts.

We’ve heard rumors that Intermountain is starting something big in the healthcare innovation space – so we ask Dredge to give us a little teaser of what that is, its purpose, and when we should be expecting it. Then we dig into Dredge’s use of the phrase ‘healthcare utility’ to learn more about what that is and how it will influence the future of healthcare. Finally, we conclude this episode with Dredge sharing more about the publications he’s done with Cambridge Judge Business School, Professor Stefan Scholtes.

Here’s a list of some of the publications mentioned:

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Why did Intermountain decide to get into the pharma and life sciences business?
What makes Civica Rx different than a traditional life sciences company?
What are the economic dynamics at play with Civica Rx?
Can you give us some examples of the impact of this work?
What should life sciences understand about Civica’s efforts?
I hear you are starting something big in the healthcare innovation space. Can you give us a little teaser of what that is, and its purpose and timeline?
You’ve often used the phrase ‘Healthcare Utility’. Can you tell us a little more about what that is and how it will influence the future of healthcare?
Tell us more about your publications that you’ve done with Cambridge Judge Business School, Professor Stefan Scholtes.

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today on your favorite podcasting platform:

Thanks so much for listening!

Anti-CRO with Lindus Health - Life Sciences Today Podcast Episode 19

Danny Lieberman and John Lynn — Fri, 25 Jul 2025 11:00:20 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Meri Beckwith, Co-Founder of Lindus Health. Lindus Health, founded by Meri Beckwith in 2021, aims to fix broken clinical trial processes. Inspired by Beckwith’s VC and trial participant experiences, it offers fixed-cost, milestone-based contracts. Its tech platform, Citrus, integrates EDC, CTMS, and CDISC-compliant storage. Focused on psychiatry and other areas, Lindus prioritizes speed, data quality, and cultural integrity as it scales across the US and UK.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about your journey.
How do you create value for your drug and device customers?
How do you measure the value?
What are 3 things you’d like to achieve in the next 12 months?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today on your favorite podcasting platform:

Thanks so much for listening!

Drug Development Data with Debiopharm - Life Sciences Today Podcast Episode 18

Danny Lieberman and John Lynn — Fri, 18 Jul 2025 11:00:57 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Frederico Braga, the Head of Digital and IT at Debiopharm, a Swiss pharmaceutical company. We talked about how they are building data infrastructure to help take the company to real-time analytics for decision making.

Debiopharm is moving from outsourcing to in-house clinical research & development. Their key rationale is: drug development data is critical IP that requires direct control. To that end, Braga is driving initiatives to implement a clinical trial management system for better oversight and build the “Debiopharm Data Fabric” – a comprehensive data pipeline system. Braga’s roadmap is a tech timeline with the full vision implementation targeted for 2026-2027.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about your journey.
How do you create value for your stakeholders?
How do you measure the value?
What are 3 things you’d like to achieve in the next 12 months?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today on your favorite podcasting platform:

Thanks so much for listening!

Connecticut's Life Sciences Industry with BioCT - Life Sciences Today Podcast Episode 17

Danny Lieberman and John Lynn — Fri, 11 Jul 2025 11:00:50 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Jodie Gillon, CEO of the Trade Organization at BioCT. Connecticut has great universities, big pharma like Pfizer, Boehringer Ingelheim, and a large number of life science startups. Gillon has built an organization with a wide web of activities, from legislation (and recently a tax credit bill that passed) to supporting startups with incubators.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about your journey to BioCT.
How do you create value?
How do you measure the value you give to the life science community in CT?
What are 3 things you’d like to achieve in the next 12 months?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today on your favorite podcasting platform:

Thanks so much for listening!

Universal Patient Record - Life Sciences Today Podcast Episode 16

Danny Lieberman and John Lynn — Thu, 03 Jul 2025 11:00:18 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Troy Astorino, Co-Founder and CTO at PicnicHealth. PicnicAI can collect medical records from everywhere in the US and transform them into meaningful data for patients, providers, and researchers. Their 8 BN parameter LLM outperforms frontier models on clinical data labeling and interpretation.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about your journey from generating over 300 million clinical annotations from clinicians to a universal health record.
What makes your product(s) unique?
How do you create value?
How do you capture value from customers?
What are 3 things holding you back from further growth?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today on your favorite podcasting platform:

Thanks so much for listening!

Oncology Trials with Flatiron Health - Life Sciences Today Podcast Episode 15

Danny Lieberman and John Lynn — Fri, 27 Jun 2025 11:00:48 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Alex Deyle, VP & General Manager, Clinical Research at Flatiron Health. Flatiron started out using humans and tech to turn unstructured data into clean, structured data and then moved on to develop their own community EHR for oncology. Today, they help pharma design clinical protocols that are more likely to succeed scientifically and commercially. They use their own EHR data to activate sites for patient enrollment and also acquire data for the clinical trial, simplifying the process and workflow of data collection and GCP assurance.

Flatiron has a unique 2-sided platform business model where sites participate for free and sponsors share success and risk with Flatiron.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

You came from IMS – how is the culture at Flatiron different from IMS Health?
What makes your product(s) unique?
How do you create value?
How do you capture value from customers?
What are 3 things holding you back from further growth?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today on your favorite podcasting platform:

Thanks so much for listening!

Medical Intelligence with Sorcero - Life Sciences Today Podcast Episode 14

Danny Lieberman and John Lynn — Fri, 20 Jun 2025 11:00:28 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Dipanwita Das, CEO at Sorcero, which provides medical intelligence to the Top 50 pharma and medical device companies. We had a great conversation talking about her journey to leading an enterprise SaaS company that helps commercial teams in pharma and devices gain confidence in the signals they get from their markets. Sorcero supports post-market surveillance and adverse event monitoring and facilitates feedback loops between clinical and medical teams. Sorcero helps track and mitigate the side effects’ impact on patient adherence. Sorcero provides a single source of truth for commercial medical intelligence to medical affairs teams, commercial teams, access teams, and pharmacovigilance teams.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

How do you create value for drug and device companies?
How do you capture value?
What are 3 things you want to achieve in the next 12-18 months? Is getting more sleep your top priority?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today on your favorite podcasting platform:

Thanks so much for listening!

Gene Therapy for Inherited Retinal Diseases - Life Sciences Today Podcast Episode 13

Danny Lieberman and John Lynn — Fri, 13 Jun 2025 11:00:42 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Dr. George Magrath, CEO at Opus Genetics, practicing ophthalmologist, and someone who’s quite literally restoring sight to the blind. Under George’s leadership, Opus is developing gene therapies for ultra-rare inherited retinal diseases, including one that recently gave a 39-year-old man the ability to see for the first time in his life. They’re also pioneering the use of AI to predict clinical outcomes and accelerate trial design.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

What made you take the leap from the clinic to launching Opus Genetics—and why now, for rare inherited retinal diseases?
You’re midway through a Phase 1/2 trial for LCA5 with big implications for patients who’ve never had treatment options. What are you hoping the data unlocks, and where do you go from here?
What does AI make possible in rare disease trials that wasn’t possible before?
How do you build a viable business model around ultra-rare diseases like LCA5 — where the science is powerful but the patient population is small?
What are the 3 things you’re most determined to achieve in the next 12–24 months — scientifically or operationally?
If we stripped away the biggest barrier in your path, what would become possible that isn’t possible today?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today on your favorite podcasting platform:

Thanks so much for listening!

Post-Surgical Care with PolyPid - Life Sciences Today Podcast Episode 12

Danny Lieberman and John Lynn — Fri, 06 Jun 2025 11:00:43 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Ori Warshavsky, COO at PolyPid. With a platform that anchors drug delivery at the point of need, PolyPid has Phase 3 programs nearing FDA submission and a pipeline that could reshape how we think about infection control, post-op healing, and localized therapeutics. Ori joins us to talk about turning science into impact.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

PolyPid was founded back in 2008, that’s a long arc in biotech. What’s new and wonderful today—and what’s different from when you started?
You’ve got five programs in the pipeline and two already in Phase 3. You’re getting close to FDA submission—what are you focused on most at this stage?
How does your anchored delivery system actually improve outcomes for patients, and where does it make the biggest difference?
How do you plan to capture value commercially, especially in markets like hospital surgery or orthopedics, where adoption can be slow?
What are the 3 things you’re most focused on achieving in the next 12–24 months—scientifically or operationally?
If you could remove one major constraint right now, what would that unlock for PolyPid?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today on your favorite podcasting platform:

Thanks so much for listening!

AI Workflows with Salt AI - Life Sciences Today Podcast Episode 11

Danny Lieberman and John Lynn — Thu, 29 May 2025 11:00:08 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. Cloud-based, visual-first AI development and collaboration platform tailored for life sciences. Designed to make AI workflows accessible to both technical and non-technical users. Salt AI enables teams to build, deploy, and scale AI-powered solutions without extensive coding expertise. My guest today is Nate Beyor – Head of Life Science at Salt AI.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Nate, can you share your career path and what led you to your current role at Salt AI?
How does Salt AI’s platform create value for life sciences researchers and organizations?
In what ways does Salt AI capture value from its services and partnerships?
What are 3 things you want to achieve in the next 12-18 months?
Why haven’t you achieved them?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today on your favorite podcasting platform:

Thanks so much for listening!

ABILITY Neurotech Challenges Neuralink - Life Sciences Today Podcast Episode 10

Danny Lieberman and John Lynn — Thu, 22 May 2025 11:00:21 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Dr. Rotem Kopel, Founder and CEO at ABILITY Neurotech.

Their implantable neural recording system is a breakthrough in Brain-Computer Interface (BCI) development, enabling robust communication pathways and enhanced autonomy for people affected by severe paralysis.

I had 2 aha moments with Rotem. The first was when I realized how different their approach is from Neuralink (you’ll have to listen to the show for that) and the second was when I realized that we are both SciFi addicts.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

What set you on the path to founding ABILITY Neurotech—and was there a moment you knew this had to exist?
Right now — are you in the lab, in the clinic, or in the boardroom?
If we fast-forward 24 months and you’ve crushed it, what 3 things did you nail?
What’s been the hardest punch in the face so far—and what did you learn from it?
Now imagine this: capital is flowing, regulators are on your side, no blockers. What are you building without friction?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today on your favorite podcasting platform:

Thanks so much for listening!

AI-Powered Data with PEAK:AIO - Life Sciences Today Podcast Episode 9

Danny Lieberman and John Lynn — Thu, 15 May 2025 11:00:01 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. I took over for Danny this episode to sit down with Mark Klarzynsk, CSO and Co-Founder at PEAK:AIO, to talk about AI-powered data! We kick this episode off by discussing the healthcare industry’s current status with AI-powered data infrastructures. Then we debate whether or not we are moving to the edge or the cloud, as well as discuss how we think this will evolve over time. Next, we take a look at the AI Data Server PEAK:AIO offers to see how it is helping to reduce the cost of bringing a drug to market and how it is contributing to sustainability in pharmaceutical manufacturing. Klarzynsk then shares with us the impact his role with the University of Strathclyde’s MediForge Hub has on drug manufacturing. We then conclude this episode by hearing about some of PEAK:AIO’s success stories with providing infrastructure to healthcare organizations.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Where are we at with AI-powered data infrastructure within the healthcare industry?
Are we moving to the edge or the cloud? How will that evolve?
How is the AI Data Server you offer helping to reduce the cost of bringing a drug to market and contributing to sustainability in pharmaceutical manufacturing?
Tell us about your role with the University of Strathclyde’s MediForge Hub and its impact on drug manufacturing.
What are some of PEAK:AIO’s success stories providing infrastructure to healthcare organizations?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today on your favorite podcasting platform:

Thanks so much for listening!

Creating Value with Videra Health - Life Sciences Today Podcast Episode 8

Danny Lieberman and John Lynn — Thu, 08 May 2025 11:00:06 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Loren Larsen, Founder and CEO at Videra Health: an AI-driven mental health assessment platform. Videra allows the patient to speak in their own words via text, chat, audio, or video. Videra automates screenings, assessments, check-ins, and monitoring for a myriad of behavioral health conditions. It’s available 24×7 for patients and never has a bad day.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about Videra — what does the company do, and who do you serve?
How does Videra create value for patients and providers?
How does Videra capture value today?
What are the 3 most important things you personally want to achieve in the next year or two?
Where will Videra be then?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today on your favorite podcasting platform:

Thanks so much for listening!

Itay&Beyond - Brain on a Chip - Life Sciences Today Podcast Episode 7

Danny Lieberman and John Lynn — Thu, 01 May 2025 11:00:36 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guests today are Dr. Nisim Peretz, Co-Founder and CEO, and Dr. Nir Waiskopf, CTO, at Itay&Beyond.

They are building what sounds like science fiction: a brain on a chip. Itay&Beyond is developing a drug discovery platform for autism spectrum disorders and neurological pathologies.

Nisim’s background spans neurobiology, hardware systems, and deep-tech innovation. His team is taking on one of the most profound challenges in science: replicating brain function outside the body to transform how we model psychiatric disorders, discover, and predict if new innovative compounds will work in the brain.

This one’s about the edge of what’s possible—and the founders who are bold enough to build there.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

What’s your backstory, Nisim? Every founder has a twist in the road. What was the trigger for starting the company? Where did the name come from?
A brain on a chip sounds like science fiction—how did this idea first take hold?
You’re bridging biology and hardware—what makes your platform unique? How is this a breakthrough?
Who are your customers, and how do you create value for them?
How will you capture value?
Where will the company be 5 years from now?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today on your favorite podcasting platform:

Thanks so much for listening!

A Nanodrug Drug Platform for Treating Acute Spinal Injuries - Life Sciences Today Podcast Episode 6

Danny Lieberman and John Lynn — Thu, 24 Apr 2025 11:00:53 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. This time I am with Dr. Lior Shaltiel, Founder and CEO at NurExone. We start this episode off with Dr. Shaltiel sharing how his personal and professional path led him to found NurExone and how he was able to get the necessary funding. Then we discuss what Dr. Shaltiel is building and why. We then take a look at his approach to see what makes it not just promising, but potentially game-changing. Next, we discuss Dr. Shaltiel’s plan to turn NurExone into a sustainable company and his profit model. We conclude this episode with Dr. Shaltiel sharing what has been his hardest day as a founder so far.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Let’s start with your story – How did your personal and professional path lead to Nurexone? And what’s the story behind how you funded the company?
What problem is Nurexone solving that no one else is getting right?
You’re targeting spinal cord injuries—a notoriously hard space. What makes your approach not just promising, but potentially game-changing?
Let’s talk business – How do you plan to turn Nurexone into a sustainable company—and what’s your model for making money while doing deep science?
What’s been your hardest day as a founder so far?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today on your favorite podcasting platform:

Thanks so much for listening!

An Autonomous AI Assistant by SOAP Health - Life Sciences Today Podcast Episode 5

Danny Lieberman and John Lynn — Thu, 17 Apr 2025 11:00:27 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. This time I am sitting down with Dr. Steven Charlap, Founder and CEO at SOAP Health to discuss SOAP Health’s autonomous AI Assistant. We start this episode by diving into Dr. Charlap’s background and what led him to found SOAP Health. Dr. Charlap then shares with us his story of why founding SOAP Health is a deeply personal mission to him. Next, we discuss the specifics of what an autonomous clinical AI assistant is and the problem it is solving today. We then move on to discuss how Dr. Charlap has been getting SOAP into the hands of its users. Lastly, we conclude this episode with a business discussion on how to capture value and who pays.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

What’s your backstory, and what led you to start SOAP Health?
You’ve shared before that this is a deeply personal mission—can you tell us that story?
For people outside the AI or clinical space, what exactly is an Autonomous Clinical AI Assistant—and what problem is it solving today?
Building in health is hard. How are you getting SOAP into the hands of users—patients, providers, and systems?
Let’s talk about business: how do you capture value, and who pays?

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today on your favorite podcasting platform:

Thanks so much for listening!

Drug Discovery and Development with AI and Deep Tech - Life Sciences Today Podcast Episode 4

Danny Lieberman and John Lynn — Fri, 11 Apr 2025 11:00:24 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest is Mati Gill — CEO at AION Labs. Today, we’re diving into the cutting edge of biotech, AI, and venture building.

Mati’s background is as unique as the model he’s leading. He’s worked at the intersection of science, pharma, and innovation for years — and now he’s helping world-class scientist-entrepreneurs turn bold ideas into sustainable businesses that serve patients around the globe.

We’ll talk today about what makes AION’s venture studio model different, how they bring pharma giants into the same room to actually build companies, and why the future of medicine may be shaped not in massive corporations, but in small, focused teams with the right support.

Whether you’re a founder, a researcher, or just curious about how AI is changing drug R&D, this conversation will give you a front-row seat.

Let’s get into it.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

What drew you to this space—AI, biotech, and venture building?
AION Labs has a powerful lineup of founding partners. What’s the core problem you’re solving — and how do you go about it differently from traditional incubators or VC models?
Instead of a go-to-market strategy for one product, you’re launching multiple startups. What’s AION’s playbook for identifying opportunities and getting those teams to real-world impact?
How do you keep patients at the center when you’re working through a web of pharma, AI, and early-stage science?
Scientist-founders often struggle with the shift from research to business. How do you support them in becoming leaders, and what does success look like for them inside your model?

Now, without further ado, we’re excited to share with you the next episode in the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today on your favorite podcasting platform:

Thanks so much for listening!

Longevity Is More Than Long Life with Centarix Biotech - Life Sciences Today Podcast Episode 3

Danny Lieberman and John Lynn — Fri, 04 Apr 2025 12:00:27 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. We all know people who seem older or younger than their age. In this episode I host Rony Angel from Centarix, a Jerusalem-based biotech company dedicated to longevity. I learned that aging has many dimensions – like bone density, balance and memory – and much richer than our biological age.

Centarix develops technology that directly slows down and even reverses the aging process on a molecular level. They are creating aging diagnostics in order to definitively assess which therapies and interventions are truly effective. They apply their research in a unique private longevity clinic in Jerusalem. Let’s dig in.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell me about yourself?
What is this longevity thing?
Centarix is the only biotech I know that is bootstrapped – tell me how that happened?What does Centarix do and what’s in the pipeline?
Tell me about your GTM with Centa Longevity clinic
How do you monetize longevity?

Now, without further ado, we’re excited to share with you the next episode in the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today on your favorite podcasting platform:

Thanks so much for listening!

Using AI to Predict How Any Patient Will Respond to Any Therapy - Life Sciences Today Podcast Episode 2

Danny Lieberman and John Lynn — Thu, 20 Mar 2025 12:00:46 -0400

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. I had the privilege of hosting Orr Inbar from Quanthealth. Quanthealth is helping us find a better way to select drugs that go into the clinic and optimize study designs to achieve positive outcomes.

Their ability to construct simulations using a large database of provider-sourced and anonymized American patient health records is impressive. They’ve done over 120 simulations to date and helped pharma improve their protocols in Phase 2 and Phase 3 clinical trials, reducing costs and times required to run studies. They’re moving upstream into Phase 1 where there is less historical data.

We’re excited to keep an eye on Quanthealth and see what they’re able to accomplish next.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Tell us about yourself and how you got into this adventure?
Quanthealth’s site mentions over 120 trial simulations—how did you choose those, and why not 1,000 or 10,000?
You reference 350 million patient records. What are the sources and how do you account for differences in standards of care across the globe?
Can you walk me through a concrete example—preferably one that wasn’t an ‘easy win’—where your platform predicted a trial outcome, and how that prediction compared to the actual results? Preferably one that wasn’t already well validated by existing PD-1/PD-L1 data
Also, is this validation retrospective or prospective?
Do customers pay you per simulation, is it a subscription model, or a hybrid? What kind of ROI or value do they see—for instance, have any trial designs actually changed based on your platform’s insights? And how do you capture value for your company?
Your August 2024 press release mentions using data from 350M patients to reduce a respiratory trial by 251 subjects and save $200M. That figure might seem high to some—can you clarify how you got that number? Did your customer actually save $200M in clinical operations?
Does the platform predict Phase 1? If you can move upstream to Phase 1 – then well, now we’re talking!
Is there anything else you’d like to share about QuantHealth or the future of trial optimization?

Now, without further ado, we’re excited to share with you the next episode in the Life Sciences Today podcast.

Be sure to subscribe to the Life Sciences Today on your favorite podcasting platform:

Thanks so much for listening!

A New Life Sciences Podcast - Life Sciences Today Podcast Episode 1

Danny Lieberman and John Lynn — Wed, 12 Mar 2025 10:00:17 -0400

We’re excited to announce the launch of the Life Sciences Today Podcast by Healthcare IT Today. We’ve been thinking about getting into the world of Life Sciences for a long time. The overlap between the topics we cover for hospitals, health systems, ambulatory practices, LTPAC, etc and the world of Life Sciences is becoming more and more. We often use the same terms like digital health and patient engagement. Plus, Life Sciences needs and wants the real world data that provider organizations have in their systems. Provider organizations need the innovations life sciences provides their patients.

The key for Healthcare IT Today to dive into life sciences was finding someone who knew the life sciences space better than we did. I’m not quite sure how the social media cosmos brought Danny Lieberman and myself together on LinkedIn, but suffice it to say that I was impressed with his work in the life sciences including his life sciences newsletter and he was interested in starting a life sciences podcast like us. A match made in heaven. And thus the Life Sciences Today podcast was born.

As was no surprise to me, we already have a long list of guests we want to have on the show. We’ve started recording a number of epsiodes and we’re excited to bring you some great content from the world of life sciences and pharma. Our current plan is to share one episode per week, but we won’t be surprised if this snowballs quickly into more epsiodes, articles, quotes, and other content. Danny will be the main host of the podcast, but I’m sure Colin Hung and myself will dive in and host episodes as well. We’re excited to see where this show will go and we’re open to innovating and changing over time. However, you can expect the usual focus on highlighting the amazing innovations and innovaters in the life sciences space.

To learn more about the new Life Sciences Today podcast, check out our first episode below where Danny and myself talk about what we expect from the podcast, the topics we plan to cover, the topics we don’t plan to cover, and our excitement for this new podcast.

Check out the main topics of discussion for episode 1 of the Life Sciences Today podcast:

Tell us a little bit about yourself and your background in Life Sciences.
Why are you passionate about what’s happening with Life Sciences today?
What are some of your goals and expectations for the Life Sciences Today podcast to start?
What kind of cadence are we planning for the podcast?
What are some of the types of guests you want to have on the Life Sciences Today podcast?
What are some of the areas we don’t plan to cover on the podcast?
Where can people find the Life Sciences Today podcast?

Now, without further ado, we’re excited to share with you episode 1 of the Life Sciences Today podcast.

As this is our first podcast, it may take a few days for your favorite platform to list Life Sciences Today. However, we’re planning to make the podcast available on all of the following podcast platforms:

Apple Podcasts
Spotify
iHeartRadio
Amazon Music
Pandora
YouTube

Note: We’ll update the platforms above with links to subscribe as each platform lists the Life Sciences Today podcast.

Thanks so much for listening!